Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • CardieX has appointed two new board members to support its global expansion strategy
  • Chris Dax has been appointed Vice President and Sean Merrit has been appointed Director of Product Innovation to support
  • With a new sales and marketing strategy, CardieX is targeting a minimum 20 per cent increase in sales for the FY2020 period

CardieX has appointed two new board members to support its global expansion strategy and sales growth.

SphygmoCor is the primary focus of AtCor’s business. The SphygmoCor technology device helps researchers detect and target organ damage and manage cardiovascular and renal disease in the early stages.

This is just one of the products CardieX and its subsidiary are driving sales for. The company is targeting at least a 20 per cent increase in sales for the 2020 period

Senior health executive, Chris Dax has been selected as the new Vice President of Operations to assist with the company’s plan. He has considerable pharmaceutical, biological and medical device, commercial and general management experience.

“Chris Dax is a 25-year medical device marketing and sales executive who will be primarily focused on expanding sales and marketing of AtCor’s medical device business as well as “new product” go-to-market strategy,” CEO Craig Cooper said.

CardieX has also appointed Sean Merrit as the Director of Product Innovation to assist with the launch of new products into the global health market.

Most recently, Sean worked for Cercacor’s consumer non-invasive patient technology device business. He was responsible for engineering, designing and product development for Cercacor’s device solutions.

“They have both hit the ground running and are already contributing significantly to our sales, revenue, product development, and marketing strategies for FY2020 and beyond,” Craig said.

CDX by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.